Osteoporosis Archives - Page 7 of 7 - Clinical Advisor

Osteoporosis

Alendronate and nonhormonal breaks?

Are there any studies on alendronate (Fosamax) therapy for nonhormonally related fractures?—Jorge Guzman-Ortiz, MD, Jayuya, P.R. There is a small but growing body of literature examining the use of bisphosphonates for the treatment of osteoporosis in patients other than postmenopausal women. Two of the largest such “at-risk” groups are men and patients being prescribed glucocorticoids…

Add a bisphosphonate to raloxifene?

A healthy, asymptomatic woman with a stable bone mineral density of -2.5 on dual energy x-ray absorptiometry (DEXA) has been taking raloxifene (Evista) for seven years along with calcium and vitamin D. She also exercises regularly. Should bisphophonates be added to the Evista? Or should the Evista be stopped and the bisphosphonates used alone for…

Male osteoporosis

A male patient with osteoporosis worries about the side effects of alendronate, particularly jaw necrosis. What are the alternatives?

Next post in Advisor Forum